StreetAlpha.app
Home › Stocks › HALO

Halozyme Therapeutics, Inc. (HALO)

Healthcare
$95.97
▼ −0.55%
LAST CLOSE · NOV 17

Halozyme licenses its ENHANZE drug delivery technology to biopharmaceutical companies and sells its own Hylenex and XYOSTED products. It last closed at $95.97 on Nov 17, down 0.55% on the day. HALO last reported earnings on Thu, Nov 5, 2026. The average 12-month price target from 8 analysts is $118.63 (+23.6% from the last close), with a high of $149.00 and a low of $79.00. Analyst consensus is Buy, based on the latest ratings from 8 firms (4 buy, 4 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in HALO, 0% of them bullish and 100% bearish. In the past 30 days there were 4 dark pool prints totaling $6.8M, the largest $3.3M.

AI Auto Pilots
Is HALO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.8B
+45.0% vs a year ago
Net income
$485.4M
−18.5% vs a year ago
EPS (diluted)
$4.00
−15.6% vs a year ago
Free cash flow
$885.9M
49.1% margin
Valuation
Market cap
$10.9B
114.0M shares
P/E
24.0
Price over 12 month EPS
Price to sales
6.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.0B
At Sep 30
Debt
$3.3B
At Sep 30
Shareholder equity
−$55.2M
Buybacks
$400.0M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $443.3M$443.3MFY2021FY2022: $660.1M$660.1MFY2022FY2023: $829.3M$829.3MFY2023FY2024: $1.0B$1.0BFY2024FY2025: $1.4B$1.4BFY2025

From HALO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · After the close (AMC)
Reported EPS
$2.39
vs $2.30 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±9.0%
Priced in before that report
Analyst consensus
Buy
Based on 8 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
8firms
4 Buy4 Hold0 Sell
Each firm's latest rating on HALO in the past 90 days
Average 12-month target
$118.63
▲ 23.6% upside

Based on 8 analysts who set a price target on HALO in the past 90 days. The average target is $118.63, with a high of $149.00 and a low of $79.00, compared with the last close of $95.97.

Low $79.00Avg $118.63High $149.00
Blue marker: last close $95.97
Highest target$149.00
Average target$118.63
Lowest target$79.00
Latest rating changes
Morgan StanleyDowngrade
Nov 11Hold$109
Leerink PartnersDowngrade
Nov 7Hold$110 → $117
CitizensTarget raised
Nov 6Buy$93 → $149
Evercore ISI GroupMaintained
Nov 6Buy$125
Wells FargoTarget raised
Nov 6Hold$95 → $110
DateFirmActionRatingPrice target
Nov 11Morgan StanleyDowngradeHold$109
Nov 7Leerink PartnersDowngradeHold$110 → $117
Nov 6CitizensTarget raisedBuy$93 → $149
Nov 6Evercore ISI GroupMaintainedBuy$125
Nov 6Wells FargoTarget raisedHold$95 → $110
Loading…

Technical Analysis

HALO · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, oversold

The stock is 22% below its 20 day and 19% below its 50 day average. It is 11% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 23), oversold. The nearest support is the Pivot S1 at $94.93, and the nearest resistance the Pivot R1 at $97.01.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 4.5%/day
Key levels
$134.0052 week high+39.6%
$116.9620 day average+21.9%
$114.0450 day average+18.8%
$104.78Swing high (Aug 11)+9.2%
$102.69100 day average+7.0%
$97.01Pivot R1+1.1%
$95.97Pivot+0.0%
$95.97Last close
$94.93Pivot S1−1.1%
$85.66200 day average−10.7%
$81.21Swing low (Jul 30)−15.4%
$61.2352 week low−36.2%
Indicators
RSI (14)23.39Oversold below 30Oversold
MACD-5.35Below its signal lineBearish
Stochastic1.9Near the bottom of its rangeOversold
ADX (14)42.3Strong downtrend
Williams %R-97.3Oversold below −80, overbought above −20Oversold
CCI (20)-111.9Oversold below −100, overbought above 100Oversold
Rate of change−25.4%Change over 10 sessionsBearish
ATR (14)$4.28Typical daily range, 4.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for HALO

What happened before

See how HALO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bearish0 bullish and 3 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow HALO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How HALO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
3
Bullish
0
0%
Bearish
3
100%
Date span
Oct 14 – Nov 16
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$6.8M
Largest print
$3.3M
Loading…

HALO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲421 buying vs 313 selling
  • ▼Held by funds -29.3 pts
  • ▲Funds holding +98
  • ▲Superinvestors: 4 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding788690+14.2%
In funds' top 102010+100.0%
Held by funds121.1%––
New / increased164 / 257101 / 276+11.7%
Reduced / sold out254 / 59208 / 75+10.6%
Put/call ratio0.620.91−31.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See HALO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HALO is in one of them and how their past HALO trades turned out.

HALO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered HALO in an article yet. Here's the latest on the wider market.

HALO Congress Trades

All congress trades →
Trades, 12 months
2
Buys
1
50%
Sells
1
50%
People
1
Last filed Oct 12
Who traded HALO · since 2017
Latest 5 filings of 9
Gilbert CisnerosSell (partial)
$1K – $15KTraded Sep 29, 2026Filed Oct 12, 2026
$1K – $15KTraded Mar 9, 2026Filed Apr 7, 2026
Gilbert CisnerosSell (partial)
$1K – $15KTraded Mar 24, 2025Filed Apr 7, 2025
Josh GottheimerSell (partial)
$1K – $15KTraded Sep 9, 2024Filed Oct 3, 2024
$15K – $50KTraded Jul 12, 2023Filed Aug 13, 2023
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CASell (partial)$1K – $15KSep 29, 2026Oct 12, 202613 d
Gilbert CisnerosD · CABuy$1K – $15KMar 9, 2026Apr 7, 202629 d
Gilbert CisnerosD · CASell (partial)$1K – $15KMar 24, 2025Apr 7, 202514 d
Josh GottheimerD · NJSell (partial)$1K – $15KSep 9, 2024Oct 3, 202424 d
Dan GoldmanD · NYSell$15K – $50KJul 12, 2023Aug 13, 202332 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Halozyme Therapeutics

Halozyme Therapeutics is a biopharmaceutical company based in San Diego, California. It licenses its ENHANZE drug delivery technology, built on a patented enzyme, to drugmakers that want to deliver injected medicines under the skin instead of through an IV. The company also develops hyperconcentrated drug formulations and auto-injector devices with pharmaceutical partners, and it sells its own Hylenex and XYOSTED products.

Headquarters
San Diego, CA
Founded
1998